SCHEMBL2620971

SCHEMBL2620971

CCc1ccc2ocnc2c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.60
ALDH1A1 P00352 6/20 0.60
KMT2A Q03164 6/20 0.60
GAA P10253 4/20 0.60
DYRK1A Q13627 1/20 0.45
RAB9A P51151 7/20 0.43
NPC1 O15118 6/20 0.43
SMN1; SMN2 Q16637 6/20 0.43
MAPT P10636 5/20 0.43
KDM4E B2RXH2 4/20 0.43
CTNNB1 P35222 4/20 0.43
WNT3A P56704 4/20 0.43
TP53 P04637 4/20 0.43
HPGD P15428 3/20 0.43
HSD17B10 Q99714 3/20 0.43
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
TRPM5 Q9NZQ8 1/20 0.40
ALOX15 P16050 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2621292 0.85 LMNA (0.48) MEN1ALDH1A1KMT2AGAADYRK1A
SCHEMBL23805614 0.82 MEN1 (0.54) MEN1ALDH1A1KMT2AGAADYRK1A
SCHEMBL19146970 0.81 MEN1 (0.53) MEN1ALDH1A1KMT2AGAADYRK1A
SCHEMBL7647470 0.81 ALDH1A1 (0.53) MEN1ALDH1A1KMT2AGAADYRK1A
SCHEMBL506532 0.81 MEN1 (0.60) MEN1ALDH1A1KMT2AGAADYRK1A
SCHEMBL30917349 0.81 MEN1 (0.60) MEN1ALDH1A1KMT2AGAADYRK1A
SCHEMBL31430609 0.81 MEN1 (0.60) MEN1ALDH1A1KMT2AGAADYRK1A
SCHEMBL3815218 0.81 MEN1 (0.60) MEN1ALDH1A1KMT2AGAADYRK1A
SCHEMBL2358986 0.81 MEN1 (0.65) MEN1ALDH1A1KMT2AGAADYRK1A
SCHEMBL2760570 0.81 MEN1 (0.60) MEN1ALDH1A1KMT2AGAADYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024166024-A1 NEW COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME 삼진제약주식회사 2024-08-15 WO disclosed
US-12030853-B2 MASP-2 inhibitors and methods of use OMEROS CORPORATION (US) 2024-07-09 US disclosed
US-20240067654-A1 OXYTOCIN RECEPTOR MODULATORS Kinoxis Therapeutics Pty Ltd (AU) 2024-02-29 US disclosed
US-20230382907-A1 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES ENLIVEN INC. 2023-11-30 US disclosed
US-11807649-B2 Fused tetracyclic quinazoline derivatives as inhibitors of ErbB2 ENLIVEN THERAPEUTICS, INC. (US) 2023-11-07 US disclosed
US-11807638-B2 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases ENLIVEN INC. (US) 2023-11-07 US disclosed
WO-2023196601-A1 OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF EIKONIZO THERAPEUTICS, INC. (US) 2023-10-12 WO disclosed
US-11767321-B2 5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases ENLIVEN INC. (US) 2023-09-26 US disclosed
US-20230203060-A1 FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) 2023-06-29 US disclosed
US-20230192705-A1 SHP2 INHIBITORS, COMPOSITIONS AND USES THEREOF BETTA PHARMACEUTICALS CO., LTD. (CN) 2023-06-22 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed
WO-2004052847-A2 TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2004-06-24 WO disclosed
EP-1100450-A2 COSMETIC COMPOSITIONS CONTAINING OPTICAL BRIGHTENERS Color Access, Inc. (US) 2001-05-23 EP disclosed
WO-2000071085-A2 COSMETIC COMPOSITIONS CONTAINING OPTICAL BRIGHTENERS COLOR ACCESS, INC. (US) 2000-11-30 WO disclosed
US-5609997-A OXAZOLE DYE, SELENIUM SENSITIZER, METAL CYANIDE COMPLEX, HIGH SPEED DEVELOPMENT, CONTRAST FUJI PHOTO FILM CO., LTD. (JP) 1997-03-11 US disclosed
EP-0289023-A2 Light-sensitive silver halide photographic material KONICA CORPORATION (JP) 1988-11-02 EP disclosed
US-4362800-A CYANINE DYES FUJI PHOTO FILM CO., LTD. (JP) 1982-12-07 US disclosed
US-4266003-A Silver halide photographic emulsions FUJI PHOTO FILM CO., LTD. (JP) 1981-05-05 US disclosed
US-4010037-A Spectrally sensitized silver halide photographic emulsion FUJI PHOTO FILM CO., LTD. (JA) 1977-03-01 US disclosed
US-3966477-A Spectrally sensitized silver halide photographic emulsion FUJI PHOTO FILM CO., LTD. (JA) 1976-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192705-A1 SHP2 INHIBITORS, COMPOSITIONS AND USES THEREOF PTPN1, PTPN7, PTPN22 MEN1 2660/4885ALDH1A1 4106/4885KMT2A 1802/4885
US-11807638-B2 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases ABL1, ABL2, BCR MEN1 4209/4885ALDH1A1 1397/4885KMT2A 450/4885
US-20240067654-A1 OXYTOCIN RECEPTOR MODULATORS OXTR, AVPR1B, AVPR1A MEN1 2771/4885ALDH1A1 3129/4885KMT2A 4547/4885
US-20230382907-A1 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES ABL1, ABL2, BCR MEN1 4209/4885ALDH1A1 1397/4885KMT2A 450/4885
US-20230203060-A1 FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF KRAS, NRAS, TP53 MEN1 408/4885ALDH1A1 3223/4885KMT2A 3065/4885
US-11767321-B2 5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases ABL1, ABL2, BCR MEN1 4209/4885ALDH1A1 1397/4885KMT2A 450/4885
US-11807649-B2 Fused tetracyclic quinazoline derivatives as inhibitors of ErbB2 ERBB2, ERBB3, BRCA1 MEN1 1359/4885ALDH1A1 4139/4885KMT2A 2957/4885
US-12030853-B2 MASP-2 inhibitors and methods of use MASP2, METAP2, SPINT2 MEN1 150/4885ALDH1A1 4709/4885KMT2A 2885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.